Nektar reports $329M cash; runway into mid-2026

NEKTAR THERAPEUTICS

Preliminary cash and cash equivalents of $329 million as of December 31, 2023.
Cash runway expected to fund operations into at least mid-2026.
Management announced at J.P. Morgan Healthcare Conference on January 10, 2024.

item 2.02 item 7.01

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-24-002718

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.